Tuesday, May 22, 2012

Medivation, Astellas submit prostate cancer drug for FDA OK

Medivation Inc. and partner Astellas Pharma Inc. could win approval of their experimental prostate cancer drug within six months, after the companies on Monday filed a new drug application with the Food and Drug Administration.
The filing isn't unexpected, but it's a big step forward for San Francisco-based Medivation (NASDAQ: MDVN). Only two years ago, the company's experimental Alzheimer's disease drug Dimebon fizzled in a Phase III trial. But a nearly 1,200-patient, late-stage study of the prostate cancer drug -- called enzalutamide, or MDV-3100 -- showed strong results.

No comments:

Post a Comment